HEIDI HEMAK: Open Payments
NPI 1669549788 · SCRANTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,065 in 92 payments from 15 companies in 2025. Trend: 2023 $2,143 · 2024 $2,509 · 2025 $2,065
Food & beverage: $1,980Education: $85
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 14 | $378 |
| ABBVIE INC. | 12 | $333 |
| Madrigal Pharmaceuticals | 12 | $315 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 16 | $192 |
| Ardelyx, Inc. | 7 | $174 |
| Aimmune Therapeutics, Inc. | 11 | $164 |
| Janssen Scientific Affairs, LLC | 1 | $99 |
| Ferring Pharmaceuticals Inc. | 3 | $84 |
| Regeneron Healthcare Solutions, Inc. | 3 | $68 |
| Gilead Sciences, Inc. | 2 | $57 |
Products named: TREMFYA, REZDIFFRA, XIFAXAN, IBSRELA, RINVOQ, CREON, ZENPEP, DUPIXENT.
Industry payments across PA — which companies pay providers there.
